HCA
HCA Healthcare, Inc.
NYSE: HCA · HEALTHCARE · MEDICAL CARE FACILITIES
$463.22
+2.95% today
Updated 2026-10-28
Market cap
$99.34B
P/E ratio
15.38
P/S ratio
1.31x
EPS (TTM)
$29.83
Dividend yield
0.64%
52W range
$353 – $554
Volume
1.4M
HCA Healthcare, Inc. (HCA) Insider transactions
Net insider activity
Net selling (36,945,955 shares)
Buy transactions
44
Sell transactions
56
All transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-08-26 | MCALEVEY, MICHAEL R | EVP & Chief Legal & Admin Off. | Sale | 7,769 | $429.00 | $3.33M |
| 2026-05-07 | MARKS, MIKE A | EVP and CFO | Sale | 3,336 | — | — |
| 2026-04-28 | SMITH, ANDREA B | Director | Buy | 509 | — | — |
| 2026-04-28 | RILEY, WAYNE JOSEPH | Director | Buy | 509 | — | — |
| 2026-04-28 | MICHELSON, MICHAEL W | Director | Buy | 925 | — | — |
| 2026-04-28 | JOHNSTON, HUGH F | Director | Buy | 809 | — | — |
| 2026-04-28 | FRIST, WILLIAM R | Director, 10% Owner | Buy | 809 | — | — |
| 2026-04-28 | FRIST, THOMAS F III | Director, 10% Owner | Buy | 1,041 | — | — |
| 2026-04-28 | DEPARLE, NANCY ANN | Director | Buy | 509 | — | — |
| 2026-04-28 | CHIDSEY, JOHN | Director | Buy | 809 | — | — |
| 2026-02-18 | MCALEVEY, MICHAEL R | EVP & Chief Legal & Admin Off. | Sale | 1,694 | $533.37 | $903536.74 |
| 2026-02-13 | MCALEVEY, MICHAEL R | EVP & Chief Legal & Admin Off. | Sale | 5,000 | — | — |
| 2026-02-13 | MCALEVEY, MICHAEL R | EVP & Chief Legal & Admin Off. | Buy | 5,000 | $236.61 | $1.18M |
| 2026-02-13 | MCALEVEY, MICHAEL R | EVP & Chief Legal & Admin Off. | Sale | 3,306 | $540.29 | $1.79M |
| 2026-02-11 | WYATT, CHRISTOPHER F. | SVP & Controller | Sale | 4,000 | $505.00 | $2.02M |
| 2026-02-11 | BERRES, JENNIFER | SVP & Chief Human Res. Officer | Sale | 4,010 | $503.00 | $2.02M |
| 2026-02-10 | WYATT, CHRISTOPHER F. | SVP & Controller | Buy | 3,350 | — | — |
| 2026-02-10 | WYATT, CHRISTOPHER F. | SVP & Controller | Sale | 1,034 | $502.05 | $519119.70 |
| 2026-02-10 | ROSSITTO, ERICA | SVP & Chief Nurse Executive | Buy | 1,676 | — | — |
| 2026-02-10 | ROSSITTO, ERICA | SVP & Chief Nurse Executive | Sale | 418 | $502.05 | $209856.90 |
| 2026-02-10 | MCALEVEY, MICHAEL R | EVP & Chief Legal & Admin Off. | Buy | 8,372 | — | — |
| 2026-02-10 | MCALEVEY, MICHAEL R | EVP & Chief Legal & Admin Off. | Sale | 3,006 | $502.05 | $1.51M |
| 2026-02-10 | MARKS, MIKE A | EVP and CFO | Buy | 5,026 | — | — |
| 2026-02-10 | MARKS, MIKE A | EVP and CFO | Sale | 1,690 | $502.05 | $848464.50 |
| 2026-02-10 | HAZEN, SAMUEL N | Director, CEO | Buy | 54,934 | — | — |
| 2026-02-10 | HAZEN, SAMUEL N | Director, CEO | Sale | 21,323 | $502.05 | $10.71M |
| 2026-02-10 | FOSTER, JON M | EVP and COO | Buy | 15,696 | — | — |
| 2026-02-10 | FOSTER, JON M | EVP and COO | Sale | 5,888 | $502.05 | $2.96M |
| 2026-02-10 | CUFFE, MICHAEL S. | EVP and Chief Clinical Officer | Buy | 9,628 | — | — |
| 2026-02-10 | CUFFE, MICHAEL S. | EVP and Chief Clinical Officer | Sale | 3,501 | $502.05 | $1.76M |
| 2026-02-10 | BERRES, JENNIFER | SVP & Chief Human Res. Officer | Buy | 7,116 | — | — |
| 2026-02-10 | BERRES, JENNIFER | SVP & Chief Human Res. Officer | Sale | 2,515 | $502.05 | $1.26M |
| 2026-02-06 | HERCULES, HOLDING II | 10% Owner | Sale | 36,629,188 | — | — |
| 2026-02-06 | FRIST, WILLIAM R | Director, 10% Owner | Sale | 36,629,188 | — | — |
| 2026-02-06 | FRIST, WILLIAM R | Director, 10% Owner | Buy | 36,557,141 | — | — |
| 2026-02-06 | FRIST, THOMAS F JR | 10% Owner | Sale | 36,629,188 | — | — |
| 2026-02-06 | FRIST, THOMAS F JR | 10% Owner | Buy | 36,557,141 | — | — |
| 2026-02-06 | FRIST, THOMAS F III | Director, 10% Owner | Sale | 36,629,188 | — | — |
| 2026-02-06 | FRIST, THOMAS F III | Director, 10% Owner | Buy | 36,557,141 | — | — |
| 2026-02-06 | FRISCO, HOLDING II | 10% Owner | Sale | 36,629,188 | — | — |
| 2026-02-06 | FRISCO, HOLDING II | 10% Owner | Buy | 36,557,141 | — | — |
| 2026-02-06 | ELCAN, PATRICIA F | 10% Owner | Sale | 36,629,188 | — | — |
| 2026-02-06 | ELCAN, PATRICIA F | 10% Owner | Buy | 36,557,141 | — | — |
| 2026-02-05 | WYATT, CHRISTOPHER F. | SVP & Controller | Sale | 10,670 | — | — |
| 2026-02-05 | WYATT, CHRISTOPHER F. | SVP & Controller | Buy | 10,670 | $139.06 | $1.48M |
| 2026-02-05 | WYATT, CHRISTOPHER F. | SVP & Controller | Sale | 5,674 | $513.76 | $2.92M |
| 2026-02-05 | FOSTER, JON M | EVP and COO | Sale | 29,330 | — | — |
| 2026-02-05 | FOSTER, JON M | EVP and COO | Buy | 29,330 | $139.06 | $4.08M |
| 2026-02-05 | FOSTER, JON M | EVP and COO | Sale | 16,076 | $513.76 | $8.26M |
| 2026-02-04 | HAZEN, SAMUEL N | Director, CEO | Buy | 1,045 | $498.35 | $520775.75 |
| 2026-02-03 | HAZEN, SAMUEL N | Director, CEO | Sale | 14,716 | $502.95 | $7.40M |
| 2026-02-03 | HAZEN, SAMUEL N | Director, CEO | Sale | 7,395 | $500.69 | $3.70M |
| 2026-02-03 | HAZEN, SAMUEL N | Director, CEO | Sale | 6,189 | $500.02 | $3.09M |
| 2026-02-03 | HAZEN, SAMUEL N | Director, CEO | Sale | 5,162 | $498.80 | $2.57M |
| 2026-02-03 | HAZEN, SAMUEL N | Director, CEO | Sale | 5,002 | $502.15 | $2.51M |
| 2026-02-03 | HAZEN, SAMUEL N | Director, CEO | Sale | 4,293 | $498.12 | $2.14M |
| 2026-02-03 | HAZEN, SAMUEL N | Director, CEO | Sale | 120 | $497.18 | $59661.40 |
| 2026-02-03 | CUFFE, MICHAEL S. | EVP and Chief Clinical Officer | Sale | 4,050 | — | — |
| 2026-02-03 | CUFFE, MICHAEL S. | EVP and Chief Clinical Officer | Sale | 1,500 | $498.09 | $747135.15 |
| 2026-01-30 | HAZEN, SAMUEL N | Director, CEO | Sale | 84,360 | — | — |
| 2026-01-30 | HAZEN, SAMUEL N | Director, CEO | Buy | 84,360 | $81.96 | $6.91M |
| 2026-01-30 | HAZEN, SAMUEL N | Director, CEO | Sale | 41,483 | $488.27 | $20.25M |
| 2026-01-29 | WYATT, CHRISTOPHER F. | SVP & Controller | Buy | 2,560 | — | — |
| 2026-01-29 | MCALEVEY, MICHAEL R | EVP & Chief Legal & Admin Off. | Buy | 8,067 | — | — |
| 2026-01-29 | MARKS, MIKE A | EVP and CFO | Buy | 11,945 | — | — |
| 2026-01-29 | HAZEN, SAMUEL N | Director, CEO | Buy | 55,846 | — | — |
| 2026-01-29 | FOSTER, JON M | EVP and COO | Buy | 11,945 | — | — |
| 2026-01-29 | CUFFE, MICHAEL S. | EVP and Chief Clinical Officer | Buy | 8,067 | — | — |
| 2026-01-29 | BERRES, JENNIFER | SVP & Chief Human Res. Officer | Buy | 6,206 | — | — |
| 2025-11-14 | HAZEN, SAMUEL N | Director, CEO | Sale | 14,830 | — | — |
| 2025-11-05 | MCALEVEY, MICHAEL R | EVP & Chief Legal & Admin Off. | Sale | 3,892 | $473.79 | $1.84M |
| 2025-11-05 | MARKS, MIKE A | EVP and CFO | Sale | 165 | — | — |
| 2025-11-03 | MCALEVEY, MICHAEL R | EVP & Chief Legal & Admin Off. | Sale | 13,170 | — | — |
| 2025-11-03 | MCALEVEY, MICHAEL R | EVP & Chief Legal & Admin Off. | Buy | 13,170 | $236.61 | $3.12M |
| 2025-11-03 | MCALEVEY, MICHAEL R | EVP & Chief Legal & Admin Off. | Sale | 9,278 | $461.56 | $4.28M |
| 2025-11-03 | MARKS, MIKE A | EVP and CFO | Sale | 165 | — | — |
| 2025-10-31 | HAZEN, SAMUEL N | Director, CEO | Sale | 58,050 | — | — |
| 2025-10-31 | HAZEN, SAMUEL N | Director, CEO | Buy | 58,050 | $69.58 | $4.04M |
| 2025-10-31 | HAZEN, SAMUEL N | Director, CEO | Sale | 28,173 | $459.68 | $12.95M |
| 2025-09-08 | CUFFE, MICHAEL S. | EVP and Chief Clinical Officer | Sale | 3,836 | $418.84 | $1.61M |
| 2025-09-04 | CUFFE, MICHAEL S. | EVP and Chief Clinical Officer | Sale | 10,920 | — | — |
| 2025-09-04 | CUFFE, MICHAEL S. | EVP and Chief Clinical Officer | Buy | 10,920 | $173.12 | $1.89M |
| 2025-09-04 | CUFFE, MICHAEL S. | EVP and Chief Clinical Officer | Sale | 7,084 | $411.59 | $2.92M |
| 2025-07-29 | CHIDSEY, JOHN | Director | Buy | 496 | — | — |
| 2025-05-13 | HAZEN, SAMUEL N | Director, CEO | Buy | 90,076 | — | — |
| 2025-05-13 | FOSTER, JON M | EVP and COO | Sale | 15,925 | $367.20 | $5.85M |
| 2025-05-13 | FOSTER, JON M | EVP and COO | Sale | 15,698 | $369.32 | $5.80M |
| 2025-05-13 | FOSTER, JON M | EVP and COO | Sale | 2,075 | — | — |
| 2025-05-13 | FOSTER, JON M | EVP and COO | Sale | 1,080 | — | — |
| 2025-05-07 | MARKS, MIKE A | EVP and CFO | Sale | 285 | $356.84 | $101699.40 |
| 2025-05-07 | MARKS, MIKE A | EVP and CFO | Buy | 181 | — | — |
| 2025-05-07 | MARKS, MIKE A | EVP and CFO | Sale | 144 | — | — |
| 2025-05-06 | MARKS, MIKE A | EVP and CFO | Sale | 466 | — | — |
| 2025-05-06 | MARKS, MIKE A | EVP and CFO | Sale | 288 | $353.58 | $101829.60 |
| 2025-05-06 | MARKS, MIKE A | EVP and CFO | Sale | 144 | — | — |
| 2025-04-30 | FRIST, WILLIAM R | Director, 10% Owner | Buy | 10,505 | $340.60 | $3.58M |
| 2025-04-29 | SMITH, ANDREA B | Director | Buy | 645 | — | — |
| 2025-04-29 | RILEY, WAYNE JOSEPH | Director | Buy | 645 | — | — |
| 2025-04-29 | MICHELSON, MICHAEL W | Director | Buy | 1,173 | — | — |
| 2025-04-29 | JOHNSTON, HUGH F | Director | Buy | 1,026 | — | — |
Frequently asked questions
Are HCA insiders buying or selling?
Over the transactions on record, HCA insiders have been net sellers, with about $118.94M in stock sold across 56 sales, against 9 open-market purchases.
Does insider selling at HCA mean the stock will fall?
Not by itself. Most executive selling is pre-scheduled through 10b5-1 plans filed months in advance, and insiders sell for diversification, taxes, and liquidity far more often than out of any view on the price. Insider buying is the stronger signal, especially when several insiders buy around the same time, because there is usually only one reason to put personal cash into the stock.
Which HCA insiders are selling the most?
Recent selling is concentrated in a few names. HAZEN, SAMUEL N accounts for the largest share on record, with about $65.39M sold. Selling by one or two individuals matters less than broad selling across the whole leadership team, which is the pattern worth watching.